M Decressac

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. doi mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats
    Mickael Decressac
    Wallenberg Neuroscience Center, Department of Experimental Medical Sciences, Lund University, Lund, Sweden
    J Parkinsons Dis 3:13-7. 2013
  2. pmc TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity
    Mickael Decressac
    Department of Experimental Medical Sciences, Wallenberg Neuroscience Center, Lund University, 22184 Lund, Sweden
    Proc Natl Acad Sci U S A 110:E1817-26. 2013
  3. doi α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons
    Mickael Decressac
    Wallenberg Neuroscience Center, Department of Experimental Medical Sciences, Lund University, BMC A11, Lund 22184, Sweden
    Sci Transl Med 4:163ra156. 2012
  4. doi Neuropeptide Y and its role in CNS disease and repair
    M Decressac
    Wallenberg Neuroscience Center, Department of Experimental Medical Sciences, Lund University, Lund, Sweden
    Exp Neurol 238:265-72. 2012
  5. doi Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease
    M Decressac
    Wallenberg Neuroscience Center, Department of Experimental Medical Sciences, Lund University, BMC A11, Lund 22184, Sweden
    Exp Neurol 235:306-15. 2012
  6. doi Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons
    M Decressac
    Wallenberg Neuroscience Center, Department of Experimental Medical Sciences, Lund University, BMC A11, Lund 22184, Sweden
    Neurobiol Dis 45:939-53. 2012
  7. doi Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease
    M Decressac
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Cambridge CB2 2PY, UK
    Exp Neurol 226:24-32. 2010

Detail Information

Publications7

  1. doi mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats
    Mickael Decressac
    Wallenberg Neuroscience Center, Department of Experimental Medical Sciences, Lund University, Lund, Sweden
    J Parkinsons Dis 3:13-7. 2013
    ..Drugs with mTOR inhibiting activity that are actively developed in cancer research may be of interest for the management of LID in PD patients. ..
  2. pmc TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity
    Mickael Decressac
    Department of Experimental Medical Sciences, Wallenberg Neuroscience Center, Lund University, 22184 Lund, Sweden
    Proc Natl Acad Sci U S A 110:E1817-26. 2013
    ....
  3. doi α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons
    Mickael Decressac
    Wallenberg Neuroscience Center, Department of Experimental Medical Sciences, Lund University, BMC A11, Lund 22184, Sweden
    Sci Transl Med 4:163ra156. 2012
    ..These results suggest that Nurr1 is a regulator of neurotrophic factor signaling and a key player in the cellular defense against α-synuclein toxicity...
  4. doi Neuropeptide Y and its role in CNS disease and repair
    M Decressac
    Wallenberg Neuroscience Center, Department of Experimental Medical Sciences, Lund University, Lund, Sweden
    Exp Neurol 238:265-72. 2012
    ..In this review, we highlight some of the recent advances in our understanding of NPY biology and how this may help explain not only its role in health and disease, but also its possible use therapeutically...
  5. doi Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease
    M Decressac
    Wallenberg Neuroscience Center, Department of Experimental Medical Sciences, Lund University, BMC A11, Lund 22184, Sweden
    Exp Neurol 235:306-15. 2012
    ..This study suggests that the AAV-α-syn model replicates the human pathology more closely than either of the other two 6-OHDA lesion models...
  6. doi Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons
    M Decressac
    Wallenberg Neuroscience Center, Department of Experimental Medical Sciences, Lund University, BMC A11, Lund 22184, Sweden
    Neurobiol Dis 45:939-53. 2012
    ..This model provides new interesting possibilities for studies of stage-specific pathologic mechanisms and identification of targets for disease-modifying therapeutic interventions linked to early or late stages of the disease...
  7. doi Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease
    M Decressac
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Cambridge CB2 2PY, UK
    Exp Neurol 226:24-32. 2010
    ..These results suggest that NPY may be of some therapeutic interest in patients with HD, although further work is needed to ascertain exactly how it mediates its beneficial effects...